Background Image

Latest News

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

16 February 2017

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

 SAN JOSE, California and OXFORD, England, February 9, 2017

Oxford BioTherapeutics ("OBT"), an international biotechnology company developing clinical stage antibody therapeutics for cancer, today announced a significant strengthening of its oncology focused Board of Directors with the appointment of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as a non-executive director, joining Glenn Begley, Shawn Tomasello, Tom Bradley and Christian Rohlff.

Bernd Seizinger brings over 20 years of industry experience, from a number of senior executive board positions in pharma and biotech companies on both sides of the Atlantic. These include Bristol-Myers Squibb (VP oncology drug discovery and VP Corporate and Academic alliances), GPC Biotech (CEO and President), and Chairman of Aprea, Opsona and CryptoMedix.

Speaking about his appointment Dr Seizinger said "Oxford BioTherapeutics has considerable momentum, progressing an excitingimmuno-oncology and ADC pipeline, as well as our fully-funded partnered pipeline. Our corporate evolution is now driven by ourbroad-scale ability to discover and translate novel targets into biologics drug candidates with compelling in vivo anti-tumor activity."  

Jean-Pierre Bizzari brings 32 years' experience including as EVP and Group Head of Clinical Oncology at Celgene until 2015, and Sanofi Aventis prior to that, and has directed the clinical development and approval of a number of important anti-cancer medicines.

Jean-Pierre Bizzari commenting on his appointment "I am excited to be joining Oxford BioTherapeutics at this pivotal moment.  I believe the Company's broad pipeline of next generation immuno-oncology candidates against novel checkpoint targets has significant potential to produce transformative medicines."

Christian Rohlff, PhD, Oxford BioTherapeutics' chief executive officer, said " We are honored to be welcoming Bernd Seizinger as Chairman, and Jean-Pierre Bizzari as a non-executive director. These appointments of world-renowned experts will support Oxford BioTherapeutics' transition into a clinical-stage oncology therapeutics development company, with a mature, well-funded clinical ADC/C pipeline and a disruptive early second generation I-O pipeline."